8-K: Elicio's ELI-002 7P Shows Robust T-Cell Response in Phase 2

Elicio Therapeutics announced strong immunogenicity data for its ELI-002 7P cancer vaccine, achieving robust mKRAS-specific T cell responses in 99% of evaluable patients in the Phase 2 AMPLIFY-7P trial.

Summary

• ELI-002 7P induced mKRAS-specific T cell responses in 99% (89 of 90) of evaluable patients in the ongoing Phase 2 AMPLIFY-7P trial.
• Robust mKRAS-specific T cell responses were observed with an average increase of 145.3x over baseline (median 44.3x; range 2.13-1310x), consistent with prior ELI-002 Phase 1 trial results.
• T cell responses included both mKRAS-specific CD4 and CD8 T cells in 85% of patients, an increase from 75% in the previous Phase 1 trial of ELI-002 7P.
• 67.4% of patients exhibited responses for all seven mKRAS antigens, compared to 50% in the Phase 1 trial of ELI-002 7P.
• An 87.6% response rate to patient-specific mKRAS tumor antigen was observed, compared to 83.3% in the ELI-002 7P Phase 1 trial.
• Overall vaccine immunogenicity showed positive T cell responses to 85.7% of vaccine antigens, compared to 66.7% in the ELI-002 7P Phase 1 trial.
• An Independent Data Monitoring Committee (IDMC) recommended that the trial continue to the final analysis without modifications, which Elicio believes indicates preliminary signals of efficacy.

Sentiment

Score: 9

Explanation: The immunogenicity data from the Phase 2 AMPLIFY-7P trial is overwhelmingly positive, showing robust T-cell responses in 99% of patients and significant fold changes over baseline, consistent with and often exceeding Phase 1 results that correlated with clinical activity. The IDMC's recommendation to continue the trial without modifications further reinforces confidence in the preliminary efficacy signals. This is a strong indicator for the potential of ELI-002 7P.

Positives

• 99% mKRAS-specific T cell response rate in Phase 2 (89 of 90 evaluable patients).
• Average T cell response increase of 145.3x over baseline, significantly exceeding the ~9x threshold correlated with clinical activity in Phase 1 trials.
• Median T cell response increase of 44.3x over baseline.
• Robust T cell responses are consistent with prior Phase 1 trials, where responses correlated with clinical activity.
• Improved CD4 and CD8 response rate (85% in Phase 2 vs. 75% in Phase 1).
• Higher response rate for all seven mKRAS antigens (67.4% in Phase 2 vs. 50% in Phase 1).
• Increased response rate to patient-specific mKRAS tumor antigen (87.6% in Phase 2 vs. 83.3% in Phase 1).
• Improved overall vaccine immunogenicity (85.7% in Phase 2 vs. 66.7% in Phase 1).
• Independent Data Monitoring Committee (IDMC) recommended continuation of the Phase 2 trial to final analysis without modifications, indicating preliminary signals of efficacy.
• Potential to expand to a broader patient population (MRD-negative patients included in Phase 2) and enhance commercial opportunity if Phase 2 results are supportive.

Negatives

• The response threshold correlated with clinical activity has not yet been determined for Phase 2.
• The Company remains blinded to the Phase 2 trial clinical efficacy outcomes and any correlation between observed T cell responses and antitumor response in patients.

Risks

• No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
• New factors emerge from time to time, and it is not possible to predict all such factors or assess their impact on the business.
• The industry may not grow at the rate projected by market data, or at all, which could materially adversely affect the business and the market price of securities.
• If any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based upon these assumptions.
• Risks are more fully discussed in Elicio's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, and June 30, 2025.

Future Outlook

The final disease-free survival analysis for the Phase 2 AMPLIFY-7P trial is anticipated in the fourth quarter of 2025. If Phase 2 results are supportive, expanding to a broader patient population, including MRD-negative patients, could enable more pancreatic ductal adenocarcinoma (PDAC) patients to benefit from the vaccine and enhance commercial opportunity. Elicio plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers. The company's pipeline also includes additional off-the-shelf therapeutic cancer vaccine candidates, ELI-007 (targeting BRAF-driven cancers) and ELI-008 (targeting p53 hotspot mutations).

Management Comments

• Robert Connelly, Chief Executive Officer, commented: "We are extremely encouraged by the T cell immunogenicity data from the ongoing Phase 2 ELI-002 7P trial."
• Robert Connelly, Chief Executive Officer, stated: "The robust T cell responses observed are highly consistent with our positive Phase 1 results and further enhance our confidence in the ongoing Phase 2 trial, as T cell immune responses in ELI-002 2P and ELI-002 7P Phase 1 trials were significantly correlated with clinical activity in minimal residual disease positive (MRD+) patients."
• Robert Connelly, Chief Executive Officer, added: "These important data set the stage for the final disease-free survival analysis in the AMPLIFY-7P trial, which is anticipated to occur in the fourth quarter of 2025."
• Elicio believes the IDMC's recommendation that the Phase 2 AMPLIFY-7P trial continue to the final analysis without modifications is an indication that ELI-002 7P has shown preliminary signals of efficacy.

Industry Context

Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, particularly those driven by KRAS-gene mutations. The company's proprietary Amphiphile (AMP) platform aims to deliver immunotherapeutics directly to lymph nodes, the immune system's 'brain center,' to efficiently educate, activate, and amplify critical immune cells. This site-specific delivery is believed to produce superior clinical benefits compared to conventional vaccination strategies. Elicio is pursuing an 'off-the-shelf' vaccine approach with ELI-002, which offers potential advantages such as lower cost, rapid commercial scale manufacturing, and quick availability to patients, contrasting with personalized vaccine approaches. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC, presented at the ESMO Immuno-Oncology Congress 2024, showed promising median recurrence-free survival (16.3 months) and overall survival (28.9 months), positioning Elicio as a significant player in the cancer vaccine space.

Comparison to Industry Standards

• ELI-002 2P Phase 1 data showed a median Relapse-Free Survival (RFS) of 16.33 months and median Overall Survival (OS) of 28.94 months for the full study population (n=25), which compares favorably to historic MRD+ PDAC median RFS of 5.0-6.4 months and median OS of 17 months.
• The 88% reduction in Risk of Progression or Death due to any cause in patients with T cell responses above the 9.17x threshold in the ELI-002 2P Phase 1 trial indicates a strong therapeutic effect compared to standard care.
• Elicio's AMP platform, originally developed at the Massachusetts Institute of Technology, is designed to deliver immunotherapeutics directly to lymph nodes, a mechanism believed to drive therapeutic immune responses of increased magnitude, function, and durability compared to immunotherapies that do not engage the lymph nodes.

Stakeholder Impact

• Shareholders: Positive clinical data and IDMC recommendation could lead to increased investor confidence and potential share price appreciation. The potential for expanded patient populations and future indications could increase long-term value.
• Patients: The robust T-cell responses and preliminary efficacy signals offer hope for a new treatment option for mKRAS-driven cancers, particularly pancreatic cancer patients at high risk of relapse.
• Employees: Positive trial results strengthen the company's position and could lead to further growth and stability.
• Healthcare Providers: Successful development of ELI-002 7P could provide a new therapeutic tool for treating mKRAS-driven cancers.

Next Steps

• Final disease-free survival analysis in the AMPLIFY-7P trial, anticipated in the fourth quarter of 2025.
• Potential expansion of ELI-002 to a broader patient population (including MRD-negative patients) if Phase 2 results are supportive.
• Future expansion of ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers.
• Continued development of other off-the-shelf therapeutic cancer vaccine candidates, ELI-007 (BRAF-driven cancers) and ELI-008 (p53 hotspot mutations).

Key Dates

Recommendation

The robust immunogenicity data from the Phase 2 AMPLIFY-7P trial, demonstrating mKRAS-specific T cell responses in 99% of evaluable patients with an average 145.3x increase over baseline, is highly compelling. These results are consistent with and often superior to Phase 1 data, where T cell responses correlated significantly with clinical activity. The Independent Data Monitoring Committee's recommendation to continue the trial without modifications further validates the preliminary efficacy signals. While clinical efficacy outcomes remain blinded, the strong immunogenicity profile, coupled with the potential for broader patient populations and future indications, positions Elicio Therapeutics favorably. The off-the-shelf nature of the vaccine also presents a significant commercial advantage. This filing provides strong positive indicators for the company's lead candidate and future prospects, warranting a 'strong buy' recommendation for long-term investors.

Keywords

Elicio Therapeutics, ELI-002 7P, AMPLIFY-7P, Phase 2 trial, mKRAS, T cell response, cancer vaccine, immunotherapy, pancreatic cancer, colorectal cancer, biotechnology, clinical-stage, AMP platform, oncology